Core Insights - LifeMD, Inc. is integrating with LillyDirect pharmacy provider Gifthealth to enhance access to Lilly's obesity treatment Zepbound for eligible patients [1][2] - The integration aims to provide a seamless fulfillment process for Zepbound, which is now available at reduced prices through the self-pay pharmacy channel [3][4] - LifeMD's weight management program has grown to approximately 75,000 active patient subscribers as of February 2025, positioning the company as a leader in the weight-loss market [3] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions [5] - The company utilizes a vertically integrated digital care platform and has a 50-state affiliated medical group, enhancing access to affordable healthcare [5] Product Details - Zepbound is the first FDA-approved dual GLP-1 receptor agonist and GIP obesity medication, available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses through LillyDirect [2][4] - Recent price reductions for the 2.5 mg and 5 mg vials, along with the launch of new doses, aim to make the treatment more accessible [4]
LifeMD® Announces Integration with LillyDirect Pharmacy Provider to Offer Patients Streamlined Access to Branded Dual GLP-1/GIP Zepbound